Hims & Hers Health Inc (NYSE: HIMS)’s stock price has gone decline by -0.32 in comparison to its previous close of 27.94, however, the company has experienced a 9.60% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-01-19 that Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA’s negative outlook contrasts with Hims’ projected 90% YoY Q4 growth and strong non-GLP-1 business expansion. Hims’ innovative product launches, such as meal replacement bars, highlight its focus on personalized health services and continuous growth potential.
Is It Worth Investing in Hims & Hers Health Inc (NYSE: HIMS) Right Now?
The price-to-earnings ratio for Hims & Hers Health Inc (NYSE: HIMS) is 64.42x, which is above its average ratio. Moreover, the 36-month beta value for HIMS is 1.30. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 7 as “hold,” and 1 as “sell.”
The public float for HIMS is 177.47M and currently, short sellers hold a 29.37% of that float. On January 20, 2025, HIMS’s average trading volume was 15.88M shares.
HIMS’s Market Performance
HIMS stock saw a decrease of 9.60% in the past week, with a monthly decline of -10.88% and a quarterly a decrease of 24.55%. The volatility ratio for the week is 7.98%, and the volatility levels for the last 30 days are 7.99% for Hims & Hers Health Inc (HIMS). The simple moving average for the last 20 days is 4.20% for HIMS’s stock, with a simple moving average of 37.79% for the last 200 days.
Analysts’ Opinion of HIMS
Many brokerage firms have already submitted their reports for HIMS stocks, with Citigroup repeating the rating for HIMS by listing it as a “Sell.” The predicted price for HIMS in the upcoming period, according to Citigroup is $25 based on the research report published on January 10, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see HIMS reach a price target of $35. The rating they have provided for HIMS stocks is “Buy” according to the report published on January 07th, 2025.
Morgan Stanley gave a rating of “Overweight” to HIMS, setting the target price at $42 in the report published on December 17th of the previous year.
HIMS Trading at 1.84% from the 50-Day Moving Average
After a stumble in the market that brought HIMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.47% of loss for the given period.
Volatility was left at 7.99%, however, over the last 30 days, the volatility rate increased by 7.98%, as shares sank -10.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.15% upper at present.
During the last 5 trading sessions, HIMS rose by +9.60%, which changed the moving average for the period of 200-days by +85.79% in comparison to the 20-day moving average, which settled at $26.73. In addition, Hims & Hers Health Inc saw 15.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HIMS starting from Dudum Andrew, who proposed sale 83,994 shares at the price of $27.04 back on Jan 16 ’25. After this action, Dudum Andrew now owns shares of Hims & Hers Health Inc, valued at $2,271,414 using the latest closing price.
Okupe Oluyemi, the Chief Financial Officer of Hims & Hers Health Inc, sale 11,581 shares at $24.44 during a trade that took place back on Jan 13 ’25, which means that Okupe Oluyemi is holding 118,077 shares at $283,083 based on the most recent closing price.
Stock Fundamentals for HIMS
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.78 for the gross margin
The net margin for Hims & Hers Health Inc stands at 0.08. The total capital return value is set at 0.08. Equity return is now at value 26.35, with 19.93 for asset returns.
Based on Hims & Hers Health Inc (HIMS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 16.61.
Currently, EBITDA for the company is -19.94 million with net debt to EBITDA at -2.72. When we switch over and look at the enterprise to sales, we see a ratio of 4.59. The receivables turnover for the company is 271.53for trailing twelve months and the total asset turnover is 2.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.14.
Conclusion
To wrap up, the performance of Hims & Hers Health Inc (HIMS) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
